Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00586664 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
NCT00586664: Completed Phase 3 study, sponsored by Bausch & Lomb Incorporated.
NCT00586664 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 130 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00586664, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
Study Summary
Efficacy and safety study of bepotastine besilate ophthalmic solution in allergic conjunctivitis
Primary Outcome
Ocular Itching score: 0=None; 0.5=Intermittent tickle sensation possibly localized in the corner of the eye; 1.0=Intermittent tickle sensation involving more than the corner of the eye; 1.5=Intermittent all-over tickling sensation; 2.0=Mild continuous itch (can be localized) without desire to rub; 2.5=Moderate, diffuse continuous itch with desire to rub; 3.0=Severe itch with desire to rub; 3.5=Severe itch improved with minimal rubbing; 4.0=Incapacitating itch with irresistible urge to rub
Interventions
- DRUG placebo comparator
- DRUG Bepreve (bepotastine besilate ophthalmic solution) 1.5%
- DRUG Bepotastine Besilate Ophthalmic Solution 1.0%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
What the finished NCT00586664 record still lists
NCT00586664 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo comparator is the first listed.
NCT00586664 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00586664 about?
NCT00586664 is a clinical study titled "Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis". Efficacy and safety study of bepotastine besilate ophthalmic solution in allergic conjunctivitis
What is the current status of trial NCT00586664?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2007-10. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00586664?
The interventions under investigation include: placebo comparator (DRUG), Bepreve (bepotastine besilate ophthalmic solution) 1.5% (DRUG), Bepotastine Besilate Ophthalmic Solution 1.0% (DRUG).
Who is sponsoring clinical trial NCT00586664?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00586664's enrollment target sits among peer trials
130 1594th of 2000 higher than 404 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia